NASDAQ:BNTC Benitec Biopharma (BNTC) Stock Price, News & Analysis $14.78 -0.66 (-4.24%) As of 03:25 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Benitec Biopharma Stock (NASDAQ:BNTC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Benitec Biopharma alerts:Sign Up Key Stats Today's Range$14.42▼$15.6150-Day Range$11.94▼$16.5652-Week Range$5.74▼$17.15Volume96,387 shsAverage Volume44,665 shsMarket Capitalization$388.11 millionP/E RatioN/ADividend YieldN/APrice Target$23.83Consensus RatingBuy Company OverviewBenitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Read More… Benitec Biopharma Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks51st Percentile Overall ScoreBNTC MarketRank™: Benitec Biopharma scored higher than 51% of companies evaluated by MarketBeat, and ranked 590th out of 932 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.6 / 5Analyst RatingBuy Consensus RatingBenitec Biopharma has received a consensus rating of Buy. The company's average rating score is 3.22, and is based on 7 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageBenitec Biopharma has only been the subject of 2 research reports in the past 90 days.Read more about Benitec Biopharma's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Benitec Biopharma are expected to decrease in the coming year, from ($1.48) to ($2.31) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Benitec Biopharma is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Benitec Biopharma is -10.26, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBenitec Biopharma has a P/B Ratio of 3.31. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted1.93% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Benitec Biopharma has recently increased by 1.46%, indicating that investor sentiment is decreasing. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldBenitec Biopharma does not currently pay a dividend.Dividend GrowthBenitec Biopharma does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted1.93% of the float of Benitec Biopharma has been sold short.Short Interest Ratio / Days to CoverBenitec Biopharma has a short interest ratio ("days to cover") of 9.Change versus previous monthShort interest in Benitec Biopharma has recently increased by 1.46%, indicating that investor sentiment is decreasing. News and Social Media2.9 / 5News Sentiment1.13 News SentimentBenitec Biopharma has a news sentiment score of 1.13. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Benitec Biopharma this week, compared to 2 articles on an average week.Search Interest1 people have searched for BNTC on MarketBeat in the last 30 days. MarketBeat FollowsOnly 1 people have added Benitec Biopharma to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership2.5 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Benitec Biopharma insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,700,000.00 in company stock and sold $0.00 in company stock.Percentage Held by InsidersOnly 1.30% of the stock of Benitec Biopharma is held by insiders.Percentage Held by Institutions52.19% of the stock of Benitec Biopharma is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Benitec Biopharma's insider trading history. Receive BNTC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Benitec Biopharma and its competitors with MarketBeat's FREE daily newsletter. Email Address BNTC Stock News HeadlinesBenitec Biopharma: An Under-The-Radar And Undervalued Gene Therapy DeveloperApril 16, 2025 | seekingalpha.comBenitec Biopharma price target raised to $20 from $18 at Citizens JMPApril 12, 2025 | markets.businessinsider.comBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket change. June 18, 2025 | Crypto 101 Media (Ad)Benitec Biopharma participates in a conference call with Cantor FitzgeraldApril 8, 2025 | markets.businessinsider.comInsiders Are Loving These 5 Tech and Biotech StocksApril 2, 2025 | 247wallst.comBenitec Biopharma completes stock and warrant offeringsMarch 30, 2025 | investing.comBenitec Biopharma inks deal granting stock resale rightsMarch 29, 2025 | investing.comPiper Sandler Keeps Their Buy Rating on Benitec Biopharma (BNTC)March 28, 2025 | markets.businessinsider.comSee More Headlines BNTC Stock Analysis - Frequently Asked Questions How have BNTC shares performed this year? Benitec Biopharma's stock was trading at $12.63 on January 1st, 2025. Since then, BNTC shares have increased by 22.7% and is now trading at $15.4950. View the best growth stocks for 2025 here. How were Benitec Biopharma's earnings last quarter? Benitec Biopharma Limited (NASDAQ:BNTC) posted its quarterly earnings results on Wednesday, May, 14th. The biotechnology company reported ($0.24) earnings per share for the quarter, beating analysts' consensus estimates of ($0.36) by $0.12. When did Benitec Biopharma's stock split? Benitec Biopharma shares reverse split before market open on Wednesday, July 26th 2023. The 1-17 reverse split was announced on Wednesday, July 26th 2023. The number of shares owned by shareholders was adjusted after the closing bell on Wednesday, July 26th 2023. An investor that had 100 shares of stock prior to the reverse split would have 6 shares after the split. When did Benitec Biopharma IPO? Benitec Biopharma (BNTC) raised $0 in an initial public offering on Thursday, August 6th 2015. The company issued 0 shares at $0.00 per share. BMO Capital Markets and Maxim Group LLC served as the underwriters for the IPO and Roth Capital Partners was co-manager. Who are Benitec Biopharma's major shareholders? Top institutional shareholders of Benitec Biopharma include Infinitum Asset Management LLC (4.80%), AWM Investment Company Inc. (0.59%), GAMMA Investing LLC (0.33%) and MYDA Advisors LLC (0.22%). View institutional ownership trends. How do I buy shares of Benitec Biopharma? Shares of BNTC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Benitec Biopharma own? Based on aggregate information from My MarketBeat watchlists, some other companies that Benitec Biopharma investors own include Amarin (AMRN), Pfizer (PFE), ADMA Biologics (ADMA), AVEO Pharmaceuticals (AVEO), BioLineRx (BLRX), Exelixis (EXEL) and Sorrento Therapeutics (SRNE). Company Calendar Last Earnings5/14/2025Today6/18/2025Fiscal Year End6/30/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - BIOMED/GENE Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:BNTC CIK1808898 Webwww.benitec.com Phone510-780-0819Fax61 (0)3 9966-9923Employees20Year FoundedN/APrice Target and Rating Average Stock Price Target$23.83 High Stock Price Target$35.00 Low Stock Price Target$13.00 Potential Upside/Downside+56.1%Consensus RatingBuy Rating Score (0-4)3.22 Research Coverage9 Analysts Profitability EPS (Most Recent Fiscal Year)($1.51) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$21.75 million Net MarginsN/A Pretax MarginN/A Return on Equity-38.26% Return on Assets-35.71% Debt Debt-to-Equity Ratio0.01 Current Ratio14.80 Quick Ratio14.80 Sales & Book Value Annual Sales$80 thousand Price / Sales5,008.83 Cash FlowN/A Price / Cash FlowN/A Book Value$4.68 per share Price / Book3.26Miscellaneous Outstanding Shares26,250,000Free Float25,909,000Market Cap$400.71 million OptionableNo Data Beta0.44 Social Links Elon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free Report This page (NASDAQ:BNTC) was last updated on 6/18/2025 by MarketBeat.com Staff From Our PartnersElon’s BIGGEST warning yet?Tesla's About to Prove Everyone Wrong... Again Back in 2018, when Jeff Brown told everyone to buy Tesla… ...Brownstone Research | SponsoredYour Bank Account Is No Longer SafeWhat If Washington Declared That: YOUR Money ISN'T Actually Yours? Sounds insane, but that's exactly what ...Priority Gold | SponsoredWhen This Happens, You Don’t Wait. You Act.This same signal has appeared twice before in the past 8 years — both times, it kicked off major moves in cryp...Crypto Swap Profits | SponsoredAn AI run of epic proportions is only getting startedI just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredTrump Makes Major Crypto AnnouncementPay close attention to what I'm about to share… Most investors think Trump's pro-crypto policies will lift ...Crypto 101 Media | SponsoredElon’s End Game Is Going Live -- And It Could Make You a FortuneThe media and the so-called experts have laughed at Elon Musk his entire career. CBS called PayPal “one of ...The Oxford Club | SponsoredSorry about the swear wordWhat a huge few months for Bitcoin. First, Bitcoin hit $100,000… Then, Donald Trump pledged to create an...Manward Press | SponsoredThe Dollar Reset Nobody’s Talking AboutCould this man take down the financial system? In March, the Senate granted sweeping powers to a Harvard ec...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Benitec Biopharma Limited Please log in to your account or sign up in order to add this asset to your watchlist. Share Benitec Biopharma With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.